NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA

Current Opinion in Investigational Drugs

Volumn 11, Issue 2, 2010, Pages 225-236

  Politano, Amani D ^a   Sawyer, Robert G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; FLOPRISTIN PLUS LINOPRISTIN; LINEZOLID; MIKAMYCIN B; NXL 103; PRISTINAMYCIN; TEICOPLANIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HEADACHE; HOSPITAL INFECTION; HUMAN; LACTIC ACIDOSIS; LOOSE FECES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; MYOPATHY; NAUSEA; NONHUMAN; OPTIC NERVE DISEASE; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PNEUMONIA; RASH; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STEVENS JOHNSON SYNDROME; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG COMBINATIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; STREPTOGRAMIN A; STREPTOGRAMIN B;

EID: 77649133971     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Chemical transformations of pristinamycine II to study its mechanism of action. Le Goffc F, Capmau ML, Abbe J, Charles L, Montastier J EUR J MED CHEM 1981 16 1 69-72
2. Inhibition of protein synthesis by streptogramins and related antibiotics. Cocito C, Di Giambattista M, Nyssen E, Vannuffel P J ANTIMICROB CHEMOTHER 1997 39 Suppl A 7-13
3. Inducible erythromycin resistance in Staphylococci is encoded by a member of the ATP-binding transport super-gene family. Ross JI, Eady EA, Cove JH, Cunliffe WJ, Baumberg S, Wootton JC MOL MICROBIOL 1990 4 7 1207-1214
4. RPR202868/RPR132552, a new oral streptograminin: In vitro bacteriostatic activity. Berthaud N, Dutka-Malen S, Boisrobert V, Efremenko F, Gouin AM, Martin J, Rousseau J, Desnottes JF ICAAC 2000 40 Abs F-1835
5. RPR202868/RPR132552, a new oral streptogramin: Bactericidal activity and pharmacokinetics in a model of Streptococcus pneumoniae mouse pneumonia. Berthaud N, Huet Y, Diallo N, Bourgues A, Bussiere JC, Ferreira C, Imbault F, Selingue M, Desnottes JF ICAAC 2000 40 Abs F-1837
6. RPR202868/RPR132552, a new oral streptogramin: In vivo effcacy against experimental Staphylococcus aureus infections in mice. Berthaud N, Huet Y, Bouges A, Bussiere JC, Ferreira C, Imbault F, Selingue M, Desnottes JF ICAAC 2000 40 Abs F-1838
7. RPR202868/RPR132552, a new oral streptogramin: In vivo effcacy against experimental Streptococcus pneumoniae infections in mice. Berthaud N, Huet Y, Bougues A, Bussiere JC, Imbault F, Selingue M, Desnottes JF ICAAC 2000 40 Abs F-1839
8. Design and synthesis of RPR202868, the pristinamycin I component of RPR202868/RPR132552, a new oral streptogramin. Barriere JC, Bacque E, Berthaud N, Dutruc Rooset G, Doerfinger G, Puchault G ICAAC 2001 41 Abs 359
9. In vitro bactericidal activity of RPR202868/RPR132552, a new oral streptogramin, against Staphylococcus aureus in a Bioflm model. Berthaud N, Diallo N, Prevost B, Lannier Bonnamour S, Usatorre AD, Hodgson J ICAAC 2001 41 Abs F-360
10. In vitro postantibiotic effect of RPR202868/RPR132552, a new oral streptogramin. Dutka Malen S, Berthaud N, Boisrobert V, Efremenko F, Gouin AM, Martib J, Rousseau J, Hodgson J ICAAC 2001 41 Abs F-361
11. RPR202868/RPR132552, a new oral streptogramin: In vitro selection of resistant mutants. Dutka Malen S, Berthaud N, Sergent O, Hodgson J ICAAC 2001 41 Abs F-362
12. Comparative anti-pneumococcal activity of XRP-2868, a new oral streptogramin combination. Kelly LM, Ednie LM, Jacobs MR, Bryskier A, Couturier C, Appelbaum PC ICAAC 2002 42 Abs F1667
13. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC J ANTIMICROB CHEMOTHER 1997 40 1 135-136
14. Bactericidal activity of XRP 2868 (a new oral semi synthetic streptogramin) against Streptococcus pneumonia. Bryskier AJ, Drugeon HB, Juvin M, Couturier C ICAAC 2003 43 Abs F-2115
15. Role of each component [RPR 202868 (PI) and RPR132552 (PII)] in the bactericidal synergism of XRP 2868 (a new oral semi synthetic streptogramin) against Streptococcus pneumoniae, Haemophilus infuenzae and Staphylococcus aureus. Bryskier AJ, Drugeon HB, Juvin M, Couturier C ICAAC 2003 43 Abs F-2116
16. Comparitive activity of XRP 2868, a new oral streptogramin, compared with other streptogramins and macrolides against Haemophilus infuenza. Lin G, Pankuch GA, Jacobs MR, Appelbaum PC ICAAC 2003 43 Abs F-2117
17. Staphylococcus aureus resistant to vancomycin - United States, 2002. Sievert DM, Boulton ML, Stoltman G, Johnson D, Stobierski MG, Downes FP, Sonsel PA, Rudrik JT, Brown W, Hafeez W, Lundstrom T et al MMWR MORB MORTAL WKLY REP 2002 51 26 565-567
18. Activity of XRP 2868 against Streptococcus pneumoniae (SPN), Streptococcus pyogenes (SPY), Staphylococcus aureus (SAU), Haemophilus infuenzae (HIN) and atypical respiratory tract pathogens. Felmingham D, Robbins MJ, Shackcloth J, Dencer C, Williams LJ, Couturier C, Bryskier A ICAAC 2004 44 Abs F-1410
19. A comparison of the activities of a new oral streptogramin XRP2868 with those of quinupristin-dalfopristin against Haemophilus infuenza. Champney WS, Mabe S ICAAC 2004 44 Abs C1-1884
20. New anti-infectives company, Novexel, spun-out of the sanof-aventis Group with EUR 40 million funding from Atlas-Led Vc Group. sanof-aventis PRESS RELEASE 2004 December 06
21. Plasma bactericidal titres of NXL103, a novel oral streptogramin, after single dose administration of 0.5g, 1g and 1.5g to healthy volunteers. Lowther J, Rey J, Girard AM, Delachaume C, Hodgson J ICAAC 2005 45 Abs A-225
22. In vivo determination of the magnitude of the pharmacodynamic parameter associated with effcacy for the streptogramin, XRP 2868, against multiple bacteria in a murine infection model. Andes D, Lowther J, Craig WA ICAAC 2005 45 Abs F-2049
23. Comparative prevalence in European Union: Evaluation of the in vitro activity of NXL103 (formerly XRP2868) and macrolides against common respiratory pathogens. Bryskier A, Lowther J, Hodgson J ICAAC 2005 45 Abs F-2030
24. NXL103 - Oral streptogramin: A phase I, double-blind, single escalating oral dose study to evaluate safety, tolerability and pharmacokinetics in healthy adult male volunteers. Rangaraju M; Rey J, Hodgson J ICAAC 2006 46 Abs P-1512
25. Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus infuenza. Pankuch GA, Hoellman D, Bryskier A, Lowther J, Appelbaum PC ANTIMICROB AGENTS CHEMOTHER 2006 50 11 3914-3916
26. Effcacy of oral NXL103 against Haemophilus infuenzae and Streptococcus pneumoniae in mouse pneumonia models. Girard AM, Levasseur P, Lowther J, Rangaraju M ICAAC 2007 47 Abs F1-1694
27. Relative potency of NXL103 against selected bacterial pathogens and provisional disk test criteria. Brown SD, Traczewski MM, Lowther J ICAAC 2007 47 Abs F1-1695
28. Novexel initiates phase II clinical trial of NXL-103 for the treatment of community acquired pneumonia (CAP). Novexel PRESS RELEASE 2007 November 13
29. Antistaphylococcal activity of NXL 103 compared to other agents. McGhee P, Lowther J, Bryskier A et al ICAAC/ISDA 2008 48/46 Abs F1-365
30. Novexel reports positive phase II trial results with NXL103 in adult patients with community acquired pneumonia. Novexel PRESS RELEASE 2008 October 23
31. A review of tigecycline - The frst glycylcycline. Peterson LR INT J ANTIMICROB AGENTS 2008 32 Suppl 4 S215-S222
32. A phase II double-blind, double-dummy, multicenter study of two doses of linopristin/fopristin (NXL103) vs amoxicillin in the treatment of mild to moderate community-acquired pneumonia (CAP) in adults. Rangaraju M, Rabie W, Ponte N, Merdjan H, Tarral A, Sable CA ICAAC 2009 49 Abs L1-336
33. Effect of food, age and gender on NXL103 pharmacokinetics (PK). Tarral A, Merdjan H, Rangaraju M, Chassard D, Gourinchas E ICAAC 2009 49 Abs A1-1946
34. Combined population (pop) pharmacokinetic (PK) analysis of 6 phase I studies with NXL103. Gualano V, Felices M, Tarral A et al ICAAC 2009 49 Abs A1-1945
35. Multiple-dose safety, pharmacokinetics (PK) and pharmacodynamics (PD) of NXL103. Tarral A, Rangaraju M, Merdjan H et al ICAAC 2009 49 Abs A1-1944
36. Antibacterial activity of NXL103 (linopristin-fopristin) against methicillin-resistant Staphylococcus aureus. Pace J, Girard A, Levasseur P, Lavallade L, Platel D ICAAC 2009 49 Abs E-1965
37. Optimization of the linopristin/fopristin dose ratio in NXL103. Rangaraju M, Tarral A, Merdjan H et al ICAAC 2009 49 Abs A1-1943
38. A comparison of a new oral streptogramin XRP 2868 with quinupristin-dalfopristin against antibiotic-resistant strains of Haemophilus infuenzae, Staphylococcus aureus, and Streptococcus pneumonia. Mabe S, Champney WS CURR MICROBIOL 2005 51 6 363-366
39. Pharmacokinetic/pharmacodynamic modelling of the plasma bactericidal activity of NXL103 against Streptococcus pneumoniae and Staphylococcus aureus in phase I studies. Merdjan H, Lowther J, Girard AM, Delachaume C, Rangaraju M INT J ANTIMICROB AGENTS 2007 29 S199
40. Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and Haemophilus species. Pankuch GA, Kelly LM, Lin GR, Bryskier A, Couturier C, Jacobs MR, Appelbaum PC ANTIMICROB AGENTS CHEMOTHER 2003 47 10 3270-3274
41. In vitro activity of an oral streptogramin antimicrobial, XRP2868, against Gram-positive bacteria. Eliopoulos GM, Ferraro MJ, Wennersten CB, Moellering RC ANTIMICROB AGENTS CHEMOTHER 2005 49 7 3034-3039
42. Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli. Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT, Bryskier A ANTIMICROB AGENTS CHEMOTHER 2005 49 1 408-413
43. Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models. Andes D, Craig WA ANTIMICROB AGENTS CHEMOTHER 2006 50 1 243-249
44. Activity of a new oral streptogramin, XRP2868, against gram-positive cocci harboring various mechanisms of resistance to streptogramins. Dupuis M, Leclercq R ANTIMICROB AGENTS CHEMOTHER 2006 50 1 237-242
45. Novexel starts phase II clinical trial with NXL103 in adults with acute bacterial skin and skin structure infections (ABSSSI).Novexel PRESS RELEASE 2009 November 06
46. XRP2868 (RPR202868/RPR132552), a new oral streptogramin: Bactericidal activity and pharmacokinetics in a model of Streptococcus pneumoniae mouse pneumonia. Berthaud N, Huet Y, Diallo N INT J ANTIMICROB AGENTS 2002 19 Suppl 1 S34
47. Design, synthesis and in vitro evaluation of XRP2868, a new oral streptogramin. Bacque E, Barriere JC, Berthaud N, Desmazeau P, Dutruc-Rosset G, Dutka-Malen S, Ronan B INT J ANTIMICROB AGENTS 2002 19 Suppl 1 S33-S34
48. Antibacterial activity of NXL103 (linopristin/fopristin), against intracellular Staphylococcus aureus and effcacy following per oral administration in murine models of systemic infection. Pace J, Levasseur P, Girard AM, Lavallade L ECCMID 2009 19 Abs P-1025
49. Antibacterial activity of NXL103 (linopristin/fopristin), in vitro post-antibiotic effect, and spontaneous frequency of resistance. Pace J, Levasseur P, Girard AM, Lavallade L, Morrissey I ECCMID 2009 19 Abs P-1102
50. Activity of linopristin-fopristin (NXL103) against Streptococcus pneumoniae, Haemophilus infuenzae, and Staphylococcus aureus. McGhee P, Lin G, Pankuch G, Bryskier A, Appelbaum PC ECCMID 2009 19 Abs P-1393
51. Comparative in vitro activity of XRP 2868, a new, oral streptogramin. Felmingham D, Robbins MJ, Shackcloth J, Dencer C, Williams L, Couturier C, Bryskier A ECCMID 2005 Abs 1100
52. Recent progress in the feld of antibacterial pristinamycins. Bacque E, Barriere JC, Berthaud N CURR MED CHEM-ANTI-INFECTIVE AGENTS 2005 4 3 185-217
53. RPR202868/RPR132552, a new oral streptogramin: Intracellular activity against Staphylococcus aureus and Legionella pneumophila in murine macrophages. Berthaud N, Diallo N, Bonnamour S, Prevost B, Desnottes JF ICAAC 2000 40 Abs F-1836
54. Prevalence of inducible clindamycin resistance among community-and hospital-associated Staphylococcus aureus isolates. Patel M, Waites KB, Moser SA, Cloud GA, Hoesley CJ J CLIN MICROBIOL 2006 44 7 2481-2484
55. Antimicrobial agents in treatment of MRSA infections. Johnson MD, Decker CF DIS MON 2008 54 12 793-800
56. Future trends in the treatment of serious Gram-positive infections. Metzger R, Bonatti H, Sawyer R DRUGS TODAY 2009 45 1 33-45
57. Community-acquired pneumonia. Carbonara S, Monno L, Longo B, Angarano G CURR OPIN PULM MED 2009 15 3 261-273
58. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Jacobs MR CLIN MICROBIOL INFECT 2001 7 11 589-596
59. Mechanism of action of streptogramins and macrolides. Vannuffel P, Cocito C DRUGS 1996 51 20-30
60. Mechanisms of resistance to macrolides and lincosamides: Nature of the resistance elements and their clinical implications. Leclercq R CLIN INFECT DIS 2002 34 4 482-492
61. Macrolide-lincosamide-streptogramin B resistance phenotypes in clinical staphylococcal isolates. Cetin ES, Gunes H, Kaya S, Aridogan BC, Demirci M INT J ANTIMICROB AGENTS 2008 31 4 364-368
62. Daptomycin: A new treatment for insidious infections due to gram-positive pathogens. Cottagnoud P SWISS MED WKLY 2008 138 7-8 93-99
63. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. Miller D, Urdaneta V, Weltman A MMWR MORB MORTAL WKLY REP 2002 51 40 902
64. Biosynthesis, biotechnological production, and application of teicoplanin: Current state and perspectives. Jung HM, Jeya M, Kim SY, Moon HJ, Singh RK, Zhang YW, Lee JK APPL MICROBIOL BIOTECHNOL 2009 84 3 417-428
65. Tigecycline. Bhattacharya M, Parakh A, Narang M J POSTGRAD MED 2009 55 1 65-68
66. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: Clindamycin susceptibility as a surrogate indicator. Fuchs PC, Barry AL, Brown SD ANTIMICROB AGENTS CHEMOTHER 2000 44 10 2880-2882
67. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Singh KV, Weinstock GM, Murray BE ANTIMICROB AGENTS CHEMOTHER 2002 46 6 1845-1850
68. Linezolid: Effectiveness and safety for approved and off-label indications. Vardakas KZ, Ntziora F, Falagas ME EXPERT OPIN PHARMACOTHER 2007 8 2381-2400
69. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Mendes RE, Sader HS, Deshpande L, Jones RN DIAGN MICROBIOL INFECT DIS 2008 60 4 433-436
70. Quinupristin/dalfopristin: A therapeutic review. Allington DR, Rivey MP CLIN THER 2001 23 1 24-44